(Circulation. 1999;99:3110-3117.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Departments of Geriatric Medicine (H.K., N.K., M.M., H.M., T. Murase, T.K.) and Neurosurgery (S.M., N.H.), Graduate School of Medicine, Kyoto University, Kyoto, Japan, and Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan (T.S., T. Masaki).
Correspondence to Noriaki Kume, MD, PhD, Department of Geriatric Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. E-mail nkume{at}kuhp.kyoto-u.ac.jp
| Abstract |
|---|
|
|
|---|
Methods and ResultsUsing carotid endarterectomy specimens obtained from 21 patients and 2 samples of normal human aortas, we examined LOX-1 expression by reverse transcriptionpolymerase chain reaction and immunohistochemistry. In aortas without atherosclerosis, LOX-1 expression was undetectable by immunohistochemistry and negligible by reverse transcriptionpolymerase chain reaction. In carotid arteries, luminal endothelial cells covering early atherosclerotic lesions were more frequently positive for LOX-1 expression than those in advanced atherosclerotic lesions. Endothelial cells in the intimal neovasculature of advanced lesions also expressed LOX-1. In addition, macrophages and smooth muscle cells in the intima of advanced atherosclerotic plaques were positive for LOX-1 expression.
ConclusionsLOX-1 may play important roles in Ox-LDL uptake and subsequent functional alteration in the luminal endothelium in early atherosclerotic lesions and in intimal neovascular endothelial cells in advanced plaques. Furthermore, LOX-1 may also be involved in Ox-LDL uptake and subsequent foam cell transformation in macrophages and smooth muscle cells in the atherosclerotic intima.
Key Words: atherosclerosis cholesterol, LDL immunohistochemistry
| Introduction |
|---|
|
|
|---|
LOX-1 is a type II membrane protein that belongs to the C-type lectin
family.17 LOX-1 recognizes Ox-LDL, polyinosinic acid,
and carrageenan, but not acetylated LDL, fucoidin, or
maleylated BSA.19 The expression of LOX-1 can be induced
by the inflammatory cytokine tumor necrosis factor-
and
phorbol ester.20 In addition, fluid shear stress also
induces LOX-1 expression in cultured vascular
endothelial cells.21 These data indicate
that LOX-1 expression is dynamically regulated by
pathophysiological stimuli relevant to
atherogenesis and inflammation.
Previous studies have shown that MSR-A is expressed by macrophages in atherosclerotic lesions.22 23 24 In the vascular endothelium in various stages of atherogenesis, molecular markers of endothelial activation, including intercellular adhesion molecule-1,25 26 vascular cell adhesion molecule-1,27 E-selectin,25 and P-selectin,28 are expressed in human atherosclerotic lesions.
In the present study, therefore, we explored the expression of LOX-1 in the atherosclerotic lesions of human carotid arteries. We provide evidence that LOX-1 is expressed by luminal endothelial cells, neovascular endothelial cells, and nonendothelial cells in human atherosclerotic lesions.
| Methods |
|---|
|
|
|---|
Reverse TranscriptionPolymerase Chain Reaction Analysis
Total cellular RNA was isolated from 8
endarterectomy samples and 2 aortic tissue samples
using the method of Chomczynski and Sacchi29 after
homogenization with Trizol reagent (Gibco) using a
Polytron homogenizer (Kinematica). Total cellular RNA
(250 ng) was reverse-transcribed with random hexamer using SuperScript
(Gibco). The transcribed cDNA was used for polymerase chain reaction
(PCR) amplification with specific primers for human LOX-1
(hLOX-1) and ß-actin. Two specific primers corresponding to
the published sequences17 30 were used to amplify both
hLOX-1 (5'-TTACTCTCCATGGTGGTGC C-3' and 5'-AGTTCTGCAGC
CAGCTAAATGACAG-3') and ß-actin (5'-TGACGGGGTCACCCACACTGT
GCCCATCTA-3' and 5'-CTAGAAGCATTGCGGTGGACGATGGAGGG-3'). PCR
amplification was performed by 35 cycles of denaturation, annealing,
and elongation with Taq DNA polymerase (New England Biolabs,
Inc). PCR products were analyzed by agarose gel
electrophoresis and ethidium bromide staining.
Generation of Anti-LOX-1 Monoclonal Antibodies
A cDNA fragment corresponding to the extracellular domain of
hLOX-1 (amino acid numbers 85 through 273) was amplified by PCR and
subcloned into pQE 32 vector (Qiagen). The 6xHis-tagged recombinant
protein was expressed in Escherichia coli, purified with
Ni-NTA resin (Qiagen), and used as an antigen to immunize mice.
Hybridomas were prepared by standard procedures and screened by ELISA
and immunoblot.
Anti-bovine LOX-1 (bLOX-1) monoclonal antibody, which cross-reacts with hLOX-1, was used for double-labeled immunohistochemistry. This antibody was generated by immunizing rats with Chinese hamster ovary (CHO) cells stably expressing bLOX-1.17 Hybridomas were screened by cell-surface immunobinding to CHO cells stably expressing bLOX-1. Cross-reactivity to hLOX-1 was confirmed by cell-surface immunobinding to hLOX-1transfected CHO cells.
Anti-human von Willebrand factor monoclonal antibody was
purchased from DAKO; anti-human CD68 monoclonal antibody from DAKO; and
anti-human smooth muscle
-actin monoclonal antibody from Zymed.
Transient Transfection of hLOX-1 cDNA into CHO Cells
One milligram of the mammalian expression plasmid containing the
full length of hLOX-1 cDNA17 was transfected into CHO
cells cultured in Laboratory-Tek chamber slides (Nalge Nunc
International) by a lipofection method using Lipofectamine Plus
(Gibco). Cells were incubated for 48 hours after transfection; fixed
with cold acetone; washed with PBS; and incubated with anti-hLOX-1
monoclonal antibody, anti-bLOX-1 monoclonal antibody, nonimmune mouse
IgG (Zymed), or nonimmune rat IgG (Zymed) (1:100 dilution) for 1 hour;
and then incubated with fluorescein
isothiocyanateconjugated goat anti-mouse or anti-rat IgG antibody
(Caltag Laboratories). After being mounted with PBS and 90% (vol/vol)
glycerol, 0.1% (wt/vol) p-phenylenediamine, and
10 mmol/L NaN3, samples were covered with
glass slips and subjected to fluorescence microscopy.
Untransfected CHO cells were immunostained with the same
antibodies to serve as controls.
Single-Labeled Immunohistochemistry
An avidin-biotin complex (ABC) immunoperoxidase technique was
used as previously described.31 In brief, after being
fixed with cold acetone, frozen sections were incubated with 0.1%
BSA-PBS containing 2% normal horse serum and then with anti-hLOX-1
monoclonal antibody. The sections were then incubated with biotinylated
secondary antibodies. Endogenous peroxidase activity was
blocked by methanol containing 0.3% hydrogen peroxide, after which
avidin-biotin peroxidase complexes (ABC Elite Kit, Vector Labs) were
added. Antibody binding was visualized with 3,3'-diaminobenzidine
tetrahydrochloride (Vector Labs) and then counterstained with Mayer's
hematoxylin. Cells immunostained with nonimmune mouse IgG
(Zymed) served as negative controls.
Double-Labeled Immunohistochemistry
For double immunostaining, sections were first
incubated with the anti-bLOX-1 monoclonal antibody and biotinylated
anti-rat IgG, which was followed by incubation with an avidin-biotin
peroxidase conjugate and 3,3'-diaminobenzidine tetrahydrochloride with
nickel chloride (Vector Labs). Sections were subsequently incubated
with primary antibodies for cell-type characterization, which was
followed by incubation with alkaline phosphataselabeled anti-mouse
IgG and fast red alkaline phosphatase substrate solution (Vector
Labs).
| Results |
|---|
|
|
|---|
|
Immunoreactivities of 2 Monoclonal Antibodies With hLOX-1
A monoclonal antibody directed to hLOX-1 was generated by
immunizing mice with recombinant protein containing the extracellular
domain of hLOX-1. This anti-hLOX-1 monoclonal antibody can bind to
hLOX-1 expressed on the cell surface of CHO cells transfected by hLOX-1
cDNA (Figure 2A
). This monoclonal
antibody did not react to untransfected CHO cells (Figure 2B
).
CHO cells expressing hLOX-1 were not stained with nonimmune mouse IgG
(Figure 2C
). The cross-reactivity of the anti-bLOX-1 monoclonal
antibody to hLOX-1 was confirmed in the same way by
immunofluorescence microscopy (Figure 2D
through 2F).
|
LOX-1 Expression in Luminal Endothelial Cells Was
More Prominent in Early Atherosclerotic Lesions
Luminal endothelial cells were positive for LOX-1
expression in most sections of the human carotid arteries showing early
atherosclerotic lesions with subendothelial infiltrates
(Figure 3C
), although LOX-1 expression
was not detectable in the unaffected human aortic
endothelium (Figure 3A
). Staining of an adjacent
section with an anti-von Willebrand factor antibody (Figure 3E
) and double-labeled immunostaining (Figure 3G
) identified these LOX-1positive cells as
endothelial cells. In contrast, luminal
endothelial cells in advanced atherosclerotic plaques
were less frequently positive for LOX-1 expression (Figure 4E
). LOX-1 expression in
association with arterial luminal
endothelial cells was present in 71.4% of samples
with early lesions and in 33.3% of samples with advanced lesions
(Table 1
). These results suggest that
LOX-1 expression in luminal endothelial cells seems to
be upregulated, especially in the early stages of atherogenesis.
|
|
|
LOX-1 Expression on Endothelial Cells of
Intimal Neovasculature
In advanced atherosclerotic plaques, neovascular formation in the
intima was frequently observed. Of the segments with atherosclerotic
plaques in this study, 18 of 21 samples (85.7%) had neovessel
infiltration into the intima, which was identified by examining the
hematoxylin- and eosinstained sections. In these microvascular
endothelial cells, expression of LOX-1 was often
observed (Figure 5
). LOX-1 expression in
endothelial cells was present in 55.6% of advanced
atherosclerotic plaques with intimal neovasculature (Table 1
).
|
LOX-1 was Expressed by Intimal Macrophages and Smooth
Muscle Cells in Atherosclerotic Plaques
In addition to the vascular endothelium, cells
consisting of the neointima of advanced atherosclerotic
plaques were also positive for LOX-1 expression (Figure 4
).
These LOX-1positive nonendothelial cells were
present in all samples in this study (Table 1
). To identify
the cell types of these LOX-1positive cells in the intima,
double-labeled immunohistochemistry was performed using the
anti-bLOX-1 monoclonal antibody and monoclonal antibodies that
identify cell types. Antibodies specifically directed to smooth muscle
-actin and CD68 were used. Double-labeled immunohistochemistry
confirmed that LOX-1 expression occurred in intimal smooth muscle cells
and macrophages (Figure 4G
and 4H
). CD3-positive
T-lymphocytes in the arterial intima did not show any
significant staining with the anti-LOX-1 monoclonal antibody (data not
shown).
| Discussion |
|---|
|
|
|---|
As shown in this study, LOX-1 expression in vascular
endothelial cells was not uniform; it was more
frequently observed in early atherosclerotic lesions with
subendothelial infiltrates than in advanced
atherosclerotic plaques. Negligible expression of LOX-1 was detectable
in aortas free of atherosclerosis (as determined using
RT-PCR analysis), and LOX-1 expression in the
endothelial cells of these aortas was not detectable by
immunohistochemistry. LOX-1 is upregulated by the inflammatory
cytokine tumor necrosis factor-
,20 phorbol
ester,20 and fluid shear stress21 in cultured
bovine aortic endothelial cells. Expression of LOX-1 in
vivo, therefore, may also be upregulated in arterial
endothelial cells by these humoral and
hemodynamic factors, although regulation of LOX-1
expression in vivo remains to be fully clarified.
Most human atherosclerotic plaques contain intimal neovasculature,32 33 which consists of small vessels arising primarily from the adventitial vasa vasorum.34 Recent observations from human atherosclerotic lesions have revealed that these intimal neovascular endothelial cells express vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin, suggesting that leukocytes may be recruited into atherosclerotic plaques through these microvessels.27 35 Given the fact that LOX-1 is expressed in the endothelium of the intimal neovasculature, Ox-LDL uptake through LOX-1 in the intimal neovascular endothelium may play a significant role in the endothelial activation of these microvessels.
Previous studies have demonstrated that MSR-A is expressed by macrophages accumulated in the intima of human atherosclerotic plaques.22 24 36 In contrast, MSR-A expression by smooth muscle cells in human atherosclerotic lesions has not been demonstrated,22 24 36 although studies of hypercholesterolemic rabbits have shown that MSR-A is expressed by intimal smooth muscle cells.16 37 Taken together, LOX-1 and MSR-A may play important roles in the foam cell transformation of macrophages and smooth muscle cells. Especially in human atherosclerotic lesions, LOX-1 may play a major role in the foam cell transformation of intimal smooth muscle cells. The present immunohistochemical study revealed for the first time that LOX-1 was also expressed by macrophages and smooth muscle cells in vivo, although this novel receptor for Ox-LDL was originally identified in cultured bovine aortic endothelial cells, and it was suggested that it would be expressed mainly in vascular endothelial cells.17 These in vivo results seem to be supported by the fact that LOX-1 is expressed in human and murine macrophages, but it is expressed only weakly at best in circulatory monocytes.38 39 LOX-1 expression in cultured smooth muscle cells has also been observed (N.Kume, MD, PhD, et al, unpublished data, 1999).
Ox-LDL receptors such as CD3640 and MSR-A41 bind aged and apoptotic cells. Our recent studies have also shown that LOX-1 can bind and phagocytose aged and apoptotic cells.42 During atherogenesis, certain subpopulations of macrophages and smooth muscle cells can undergo apoptotic change43 44 ; therefore, LOX-1 may also be involved in the removal of apoptotic cells in the arterial wall and thus modulate atherosclerotic progression.
In summary, the present study provides evidence that LOX-1 is expressed in luminal endothelial cells, especially in the early stage of atherogenesis, and in intimal neovascular endothelial cells. More importantly, LOX-1 was highly expressed by macrophages and smooth muscle cells in the intima of human carotid atherosclerotic plaques. Our preliminary studies with hypercholesterolemic mice and rabbit models of atherosclerosis have revealed similar patterns of LOX-1 expression in endothelial cells, macrophages, and smooth muscle cells (data not shown), thus supporting the hypothesis that LOX-1 may play significant roles in both the foam cell transformation of macrophages and smooth muscle cells and endothelial activation. Further studies related to the regulatory mechanisms of LOX-1 expression in various cell types, as well as the pathophysiological consequences of Ox-LDL uptake through this novel Ox-LDL receptor, may provide new insights into the pathogenesis of atherosclerosis.
| Acknowledgments |
|---|
Received November 30, 1998; revision received March 18, 1999; accepted March 31, 1999.
| References |
|---|
|
|
|---|
2. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest.. 1991;64:515.[Medline] [Order article via Infotrieve]
3. Chisolm GM. Oxidized lipoproteins and leukocyte-endothelial interactions: growing evidence for multiple mechanisms. Lab Invest.. 1993;68:369371.[Medline] [Order article via Infotrieve]
4. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature.. 1993;362:801809.[Medline] [Order article via Infotrieve]
5. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest.. 1991;88:17851792.
6.
Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira
P, Krieger M. Type I macrophage scavenger receptor
contains
-helical and collagen-like coiled coils.
Nature.. 1990;343:531535.[Medline]
[Order article via Infotrieve]
7. Rohrer L, Freeman M, Kodama T, Penman M, Krieger M. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. Nature.. 1990;343:570572.[Medline] [Order article via Infotrieve]
8.
Endemann G, Stanton LW, Madden KS, Bryant CM, White
RT, Protter AA. CD36 is a receptor for oxidized low density
lipoprotein. J Biol Chem.. 1993;268:1181111816.
9. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, Nakata A, Ishigami M, Miyagawa J, Kameda-Takemura K, Kurata Y, Matsuzawa Y. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest.. 1995;96:18591865.
10.
Acton SL, Scherer PE, Lodish HF, Krieger M. Expression
cloning of SR-BI, a CD36-related class B scavenger receptor.
J Biol Chem.. 1994;269:2100321009.
11.
Murao K, Terpstra V, Green SR, Kondratenko N,
Steinberg D, Quehenberger O. Characterization of CLA-1, a
human homologue of rodent scavenger receptor BI, as a receptor for high
density lipoprotein and apoptotic thymocytes. J Biol
Chem.. 1997;272:1755117557.
12.
Ramprasad MP, Fischer W, Witztum JL, Sambrano GR,
Quehenberger O, Steinberg D. The 94- to 97-kDa mouse macrophage
membrane protein that recognizes oxidized low density lipoprotein and
phosphatidylserine-rich liposomes is identical to
macrosialin, the mouse homologue of human CD68. Proc Natl Acad
Sci U S A. 1995;92:95809584.
13.
Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger
O, Steinberg D. Cell surface expression of mouse macrosialin and human
CD68 and their role as macrophage receptors for oxidized low
density lipoprotein. Proc Natl Acad Sci U S A. 1996;93:1483314838.
14. Van Velzen AG, Da Silva RP, Gordon S, Van Berkel TJ. Characterization of a receptor for oxidized low-density lipoproteins on rat Kupffer cells: similarity to macrosialin. Biochem J.. 1997;322:411415.
15.
Krieger M, Acton S, Ashkenas J, Pearson A, Penman M,
Resnick D. Molecular flypaper, host defence, and
atherosclerosis: structure, binding properties, and
functions of macrophage scavenger receptors. J Biol
Chem.. 1993;268:45694572.
16. Bickel PE, Freeman M. Rabbit aortic smooth muscle cells express inducible macrophage scavenger receptor messenger RNA that is absent from endothelial cells. J Clin Invest.. 1992;90:14501457.
17. Sawamura T, Kume N, Aoyama T, Moriwaki H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. A novel receptor for oxidized low-density lipoprotein. Nature.. 1997;386:7377.[Medline] [Order article via Infotrieve]
18. Hoshikawa H, Sawamura T, Kakutani M, Aoyama T, Nakamura T, Masaki T. High affinity binding of oxidized LDL to mouse lectinlike oxidized LDL receptor (LOX-1). Biochem Biophys Res Commun.. 1998;245:841846.[Medline] [Order article via Infotrieve]
19.
Moriwaki H, Kume N, Sawamura T, Aoyama T, Hoshikawa H,
Ochi H, Nishi E, Masaki T, Kita T. Ligand specificity of LOX-1, a novel
endothelial receptor for oxidized low density
lipoprotein. Arterioscler Thromb Vasc Biol.. 1998;18:15411547.
20.
Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T,
Masaki T, Kita T. Inducible expression of lectinlike oxidized LDL
receptor-1 in vascular endothelial cells. Circ
Res.. 1998;83:322327.
21.
Murase T, Kume N, Korenaga R, Ando J, Sawamura T,
Masaki T, Kita T. Fluid shear stress transcriptionally induces
lectinlike oxidized LDL receptor-1 in vascular
endothelial cells. Circ Res.. 1998;83:328333.
22. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal E, Sarkioja T, Witztum JL, Steinberg D. Gene expression in macrophage-rich human atherosclerotic lesions: 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest.. 1991;87:11461152.
23. Naito M, Suzuki H, Mori T, Matsumoto A, Kodama T, Takahashi K. Coexpression of type I and type II human macrophage scavenger receptors in macrophages of various organs and foam cells in atherosclerotic lesions. Am J Pathol.. 1992;141:591599.[Abstract]
24.
Geng YJ, Holm J, Nygren S, Bruzelius M, Stemme S,
Hansson GK. Expression of the macrophage scavenger receptor in
atheroma: relationship to immune activation and the T-cell
cytokine interferon-gamma. Arterioscler Thromb Vasc
Biol.. 1995;15:19952002.
25. van der Wal AC, Das PK, Tigges AJ, Becker AE. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol.. 1992;141:14271433.[Abstract]
26. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol.. 1992;140:665673.[Abstract]
27. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, Lobb R, Alpers CE. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest.. 1993;92:945951.
28. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques: coexpression with intercellular adhesion molecule-1. Am J Pathol.. 1994;144:952961.[Abstract]
29. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem.. 1987;162:156160.[Medline] [Order article via Infotrieve]
30.
Ponte P, Ng SY, Engel J, Gunning P, Kedes L.
Evolutionary conservation in the untranslated regions of actin mRNAs:
DNA sequence of a human beta-actin cDNA. Nucleic Acids Res.. 1984;12:16871696.
31.
Sakai A, Kume N, Nish E, Tanoue K, Miyasaka M, Kita T.
P-selectin and vascular cell adhesion molecule-1 are focally expressed
in aortas of hypercholesterolemic rabbits before
intimal accumulation of macrophages and T lymphocytes.
Arterioscler Thromb Vasc Biol.. 1997;17:310316.
32. Geringer E. Intimal vascularization and atherosclerosis. J Pathol Bacteriol.. 1951;63:201211.[Medline] [Order article via Infotrieve]
33. Barger AC, Beeuwkes R III, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries: a possible role in the pathophysiology of atherosclerosis. N Engl J Med.. 1984;310:175177.[Medline] [Order article via Infotrieve]
34. Zhang Y, Cliff YJ, Schoefl GI, Higgins G. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol.. 1993;143:164172.[Abstract]
35.
O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE.
Neovascular expression of E-selectin, intercellular adhesion
molecule-1, and vascular cell adhesion molecule-1 in human
atherosclerosis and their relation to intimal leukocyte
content. Circulation.. 1996;93:672682.
36.
Luoma J, Hiltunen T, Sarkioja T, Moestrup SK, Gliemann
J, Kodama T, Nikkari T, Yla-Herttuala S. Expression of
-2-macrogloblin receptor/low density lipoprotein-related protein and
scavenger receptor in human atherosclerotic lesions. J Clin
Invest.. 1994;93:20142021.
37. Li H, Freeman MW, Libby P. Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J Clin Invest.. 1995;95:122133.
38.
Moriwaki H, Kume N, Kataoka H, Murase T, Nishi E,
Sawamura T, Masaki T, Kita T. Expression of lectinlike oxidized low
density lipoprotein receptor-1 in human and murine macrophages:
upregulated expression by TNF-
. FEBS Lett.. 1998;440:2932.[Medline]
[Order article via Infotrieve]
39. Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O. Identification of the lectinlike receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J. 1998;334:913.
40. Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest.. 1992;90:15131522.
41.
Platt N, Suzuki H, Kurihara Y, Kodama T, Gordon S. Role
for the class A macrophage scavenger receptor in the
phagocytosis of apoptotic thymocytes in vitro. Proc Natl
Acad Sci U S A. 1996;93:1245612460.
42.
Oka K, Sawamura T, Kikuta K, Itokawa S, Kume N, Kita T,
Masaki T. Lectinlike oxidized low-density lipoprotein receptor 1
mediates phagocytosis of aged/apoptotic cells in
endothelial cells. Proc Natl Acad Sci
U S A. 1998;95:95359540.
43. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol.. 1996;149:367380.[Abstract]
44. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol.. 1996;7:330335.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
L. Zhang, Y. Liu, X. T. Lu, Y. L. Wu, C. Zhang, X. P. Ji, R. Wang, C. X. Liu, J. B. Feng, H. Jiang, et al. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2004 - H2014. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sugimoto, T. Ishibashi, T. Sawamura, N. Inoue, M. Kamioka, H. Uekita, H. Ohkawara, T. Sakamoto, N. Sakamoto, Y. Okamoto, et al. LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells Cardiovasc Res, October 1, 2009; 84(1): 127 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rasouli, A. Yao-Borengasser, V. Varma, H. J. Spencer, R. E. McGehee Jr, C. A. Peterson, J. L. Mehta, and P. A. Kern Association of Scavenger Receptors in Adipose Tissue With Insulin Resistance in Nondiabetic Humans Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1328 - 1335. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Schaeffer, M. Riazy, K. S. Parhar, J. H. Chen, V. Duronio, T. Sawamura, and U. P. Steinbrecher LOX-1 augments oxLDL uptake by lysoPC-stimulated murine macrophages but is not required for oxLDL clearance from plasma J. Lipid Res., August 1, 2009; 50(8): 1676 - 1684. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Kim, H. Moradi, J. Yuan, K. Norris, and N. D. Vaziri Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1297 - F1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Eichhorn, G. Muller, A. Leuner, T. Sawamura, U. Ravens, and H. Morawietz Impaired vascular function in small resistance arteries of LOX-1 overexpressing mice on high-fat diet Cardiovasc Res, June 1, 2009; 82(3): 493 - 502. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lu, J.-H. Yang, A. R. Burns, H.-H. Chen, D. Tang, J. P. Walterscheid, S. Suzuki, C.-Y. Yang, T. Sawamura, and C.-H. Chen Mediation of Electronegative Low-Density Lipoprotein Signaling by LOX-1: A Possible Mechanism of Endothelial Apoptosis Circ. Res., March 13, 2009; 104(5): 619 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sankaralingam, Y. Xu, T. Sawamura, and S. T. Davidge Increased Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Expression in the Maternal Vasculature of Women With Preeclampsia: Role for Peroxynitrite Hypertension, February 1, 2009; 53(2): 270 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. V. Sangle, R. Zhao, and G. X. Shen Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1243 - E1254. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Brinkley, N. Kume, H. Mitsuoka, M. D. Brown, D. A. Phares, R. E. Ferrell, T. Kita, and J. M. Hagberg Variation in the human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) gene is associated with plasma soluble LOX-1 levels Exp Physiol, September 1, 2008; 93(9): 1085 - 1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Thum and J. Borlak LOX-1 Receptor Blockade Abrogates oxLDL-induced Oxidative DNA Damage and Prevents Activation of the Transcriptional Repressor Oct-1 in Human Coronary Arterial Endothelium J. Biol. Chem., July 11, 2008; 283(28): 19456 - 19464. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. B. Tan, S. W. M. Shiu, Y. Wong, L. Leng, and R. Bucala Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus J. Lipid Res., July 1, 2008; 49(7): 1438 - 1444. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Murphy, R. S. Vohra, S. Dunn, Z. G. Holloway, A. P. Monaco, S. Homer-Vanniasinkam, J. H. Walker, and S. Ponnambalam Oxidised LDL internalisation by the LOX-1 scavenger receptor is dependent on a novel cytoplasmic motif and is regulated by dynamin-2 J. Cell Sci., July 1, 2008; 121(13): 2136 - 2147. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gratchev, J. Kzhyshkowska, S. Kannookadan, M. Ochsenreiter, A. Popova, X. Yu, S. Mamidi, E. Stonehouse-Usselmann, I. Muller-Molinet, L. Gooi, et al. Activation of a TGF-{beta}-Specific Multistep Gene Expression Program in Mature Macrophages Requires Glucocorticoid-Mediated Surface Expression of TGF-{beta} Receptor II J. Immunol., May 15, 2008; 180(10): 6553 - 6565. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Marwali, C.-P. Hu, B. Mohandas, A. Dandapat, P. Deonikar, J. Chen, I. Cawich, T. Sawamura, M. Kavdia, and J. L. Mehta Modulation of ADP-Induced Platelet Activation by Aspirin and Pravastatin: Role of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1, Nitric Oxide, Oxidative Stress, and Inside-Out Integrin Signaling J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1324 - 1332. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Morawietz LOX-1 and Atherosclerosis: Proof of Concept in LOX-1-Knockout Mice Circ. Res., June 8, 2007; 100(11): 1534 - 1536. [Full Text] [PDF] |
||||
![]() |
T. Ishigaki, I. Ohki, N. Utsunomiya-Tate, and S.-i. Tate Chimeric Structural Stabilities in the Coiled-Coil Structure of the NECK Domain in Human Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 (LOX-1) J. Biochem., June 1, 2007; 141(6): 855 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kamei, K. Yoneda, N. Kume, M. Suzuki, H. Itabe, K.-i. Matsuda, T. Shimaoka, M. Minami, S. Yonehara, T. Kita, et al. Scavenger Receptors for Oxidized Lipoprotein in Age-Related Macular Degeneration Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1801 - 1807. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, X. Gao, B. J. Potter, J.-M. Cao, and C. Zhang Anti-LOX-1 Rescues Endothelial Function in Coronary Arterioles in Atherosclerotic ApoE Knockout Mice Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 871 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Moore and M. W. Freeman Scavenger Receptors in Atherosclerosis: Beyond Lipid Uptake Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1702 - 1711. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ueda, N. Kume, K. Hayashida, A. Inui-Hayashida, M. Asai, T. Kita, and G. Kominami ELISA for Soluble Form of Lectin-Like Oxidized LDL Receptor-1, A Novel Marker of Acute Coronary Syndrome. Clin. Chem., June 1, 2006; 52(6): 1210 - 1211. [Full Text] [PDF] |
||||
![]() |
A. Ghazalpour, X. Wang, A. J. Lusis, and M. Mehrabian Complex Inheritance of the 5-Lipoxygenase Locus Influencing Atherosclerosis in Mice Genetics, June 1, 2006; 173(2): 943 - 951. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Hofnagel, B. Luechtenborg, H. Eschert, G. Weissen-Plenz, N. J. Severs, and H. Robenek Pravastatin Inhibits Expression of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1) in Watanabe Heritable Hyperlipidemic Rabbits: A New Pleiotropic Effect of Statins Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 604 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Mehta, J. Chen, P. L. Hermonat, F. Romeo, and G. Novelli Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders Cardiovasc Res, January 1, 2006; 69(1): 36 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chen, J. Chen, Y. Liu, J. Xie, D. Li, T. Sawamura, P. L. Hermonat, and J. L. Mehta Adhesion Molecule Expression in Fibroblasts: Alteration in Fibroblast Biology After Transfection With LOX-1 Plasmids Hypertension, September 1, 2005; 46(3): 622 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hayashida, N. Kume, T. Murase, M. Minami, D. Nakagawa, T. Inada, M. Tanaka, A. Ueda, G. Kominami, H. Kambara, et al. Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome: A Novel Marker for Early Diagnosis Circulation, August 9, 2005; 112(6): 812 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Inoue, Y. Arai, H. Kurihara, T. Kita, and T. Sawamura Overexpression of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Induces Intramyocardial Vasculopathy in Apolipoprotein E-Null Mice Circ. Res., July 22, 2005; 97(2): 176 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mango, S. Biocca, F. del Vecchio, F. Clementi, F. Sangiuolo, F. Amati, A. Filareto, S. Grelli, P. Spitalieri, I. Filesi, et al. In Vivo and In Vitro Studies Support That a New Splicing Isoform of OLR1 Gene Is Protective Against Acute Myocardial Infarction Circ. Res., July 22, 2005; 97(2): 152 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kazi, C. Zhu, J. Roy, G. Paulsson-Berne, A. Hamsten, J. Swedenborg, U. Hedin, and P. Eriksson Difference in Matrix-Degrading Protease Expression and Activity Between Thrombus-Free and Thrombus-Covered Wall of Abdominal Aortic Aneurysm Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1341 - 1346. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Park, F. G. Adsit, and J. C. Boyington The 1.4 A Crystal Structure of the Human Oxidized Low Density Lipoprotein Receptor Lox-1 J. Biol. Chem., April 8, 2005; 280(14): 13593 - 13599. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Greaves and S. Gordon Thematic review series: The Immune System and Atherogenesis. Recent insights into the biology of macrophage scavenger receptors J. Lipid Res., January 1, 2005; 46(1): 11 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Fach, L.-A. Garulacan, J. Gao, Q. Xiao, S. M. Storm, Y. P. Dubaquie, S. A. Hefta, and G. J. Opiteck In Vitro Biomarker Discovery for Atherosclerosis by Proteomics Mol. Cell. Proteomics, December 1, 2004; 3(12): 1200 - 1210. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Honjo, T. Sawamura, J. Hinagata, K. Nakamura, N. Sanada, H. Tanihara, Y. Honda, and J. Kiryu Expression of LOX-1, an Oxidized Low-Density Lipoprotein Receptor, in Choroidal Neovascularization Arch Ophthalmol, December 1, 2004; 122(12): 1873 - 1876. [Full Text] [PDF] |
||||
![]() |
J.L. Mehta, J. Chen, F. Yu, and D.Y. Li Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells Cardiovasc Res, November 1, 2004; 64(2): 243 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, N. Roumeliotis, T. Sawamura, and G. Renier C-Reactive Protein Enhances LOX-1 Expression in Human Aortic Endothelial Cells: Relevance of LOX-1 to C-Reactive Protein-Induced Endothelial Dysfunction Circ. Res., October 29, 2004; 95(9): 877 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Hofnagel, B. Luechtenborg, K. Stolle, S. Lorkowski, H. Eschert, G. Plenz, and H. Robenek Proinflammatory Cytokines Regulate LOX-1 Expression in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1789 - 1795. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Melo, M. Gnecchi, A. S. Pachori, D. Kong, K. Wang, X. Liu, R. E. Pratt, and V. J. Dzau Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1761 - 1774. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. V. Smirnova, M. Kajstura, T. Sawamura, and M. S. Goligorsky Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H782 - H790. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, T. Sawamura, and G. Renier Glucose Enhances Human Macrophage LOX-1 Expression: Role for LOX-1 in Glucose-Induced Macrophage Foam Cell Formation Circ. Res., April 16, 2004; 94(7): 892 - 901. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kume and T. Kita Apoptosis of Vascular Cells by Oxidized LDL: Involvement of Caspases and LOX-1 and Its Implication in Atherosclerotic Plaque Rupture Circ. Res., February 20, 2004; 94(3): 269 - 270. [Full Text] [PDF] |
||||
![]() |
J. L. Mehta, B. Hu, J. Chen, and D. Li Pioglitazone Inhibits LOX-1 Expression in Human Coronary Artery Endothelial Cells by Reducing Intracellular Superoxide Radical Generation Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2203 - 2208. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Holven, H. Scholz, B. Halvorsen, P. Aukrust, L. Ose, and M. S. Nenseter Hyperhomocysteinemic Subjects Have Enhanced Expression of Lectin-Like Oxidized LDL Receptor-1 in Mononuclear Cells J. Nutr., November 1, 2003; 133(11): 3588 - 3591. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Akiba, Y. Yoneda, S. Ohno, M. Nemoto, and T. Sato Oxidized LDL activates phospholipase A2 to supply fatty acids required for cholesterol esterification J. Lipid Res., September 1, 2003; 44(9): 1676 - 1685. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Walton, X. Hsieh, N. Gharavi, S. Wang, G. Wang, M. Yeh, A. L. Cole, and J. A. Berliner Receptors Involved in the Oxidized 1-Palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated Synthesis of Interleukin-8: A ROLE FOR TOLL-LIKE RECEPTOR 4 AND A GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEIN J. Biol. Chem., August 8, 2003; 278(32): 29661 - 29666. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, L. Liu, H. Chen, T. Sawamura, and J. L. Mehta LOX-1, an Oxidized LDL Endothelial Receptor, Induces CD40/CD40L Signaling in Human Coronary Artery Endothelial Cells Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 816 - 821. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, V. Williams, L. Liu, H. Chen, T. Sawamura, F. Romeo, and J. L. Mehta Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction J. Am. Coll. Cardiol., March 19, 2003; 41(6): 1048 - 1055. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Honjo, K. Nakamura, K. Yamashiro, J. Kiryu, H. Tanihara, L. M. McEvoy, Y. Honda, E. C. Butcher, T. Masaki, and T. Sawamura Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation PNAS, February 4, 2003; 100(3): 1274 - 1279. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, L. Liu, H. Chen, T. Sawamura, S. Ranganathan, and J. L. Mehta LOX-1 Mediates Oxidized Low-Density Lipoprotein-Induced Expression of Matrix Metalloproteinases in Human Coronary Artery Endothelial Cells Circulation, February 4, 2003; 107(4): 612 - 617. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Y. Li, H. J. Chen, E. D. Staples, K. Ozaki, B. Annex, B. K. Singh, R. Vermani, and J. L. Mehtat Oxidized Low-Density Lipoprotein Receptor LOX-1 and Apoptosis in Human Atherosclerotic Lesions Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2002; 7(3): 147 - 153. [Abstract] [PDF] |
||||
![]() |
D. Li, H. Chen, F. Romeo, T. Sawamura, T. Saldeen, and J. L. Mehta Statins Modulate Oxidized Low-Density Lipoprotein-Mediated Adhesion Molecule Expression in Human Coronary Artery Endothelial Cells: Role of LOX-1 J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 601 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Mehta and D. Li Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1429 - 1435. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Hofnagel, B. Luechtenborg, G. Plenz, H. Robenek, and N. Kume Expression of the Novel Scavenger Receptor SR-PSOX in Cultured Aortic Smooth Muscle Cells and Umbilical Endothelial Cells Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 710 - 711. [Full Text] [PDF] |
||||
![]() |
M. Locati, U. Deuschle, M. L. Massardi, F. O. Martinez, M. Sironi, S. Sozzani, T. Bartfai, and A. Mantovani Analysis of the Gene Expression Profile Activated by the CC Chemokine Ligand 5/RANTES and by Lipopolysaccharide in Human Monocytes J. Immunol., April 1, 2002; 168(7): 3557 - 3562. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Minami, N. Kume, T. Shimaoka, H. Kataoka, K. Hayashida, Y. Akiyama, I. Nagata, K. Ando, M. Nobuyoshi, M. Hanyuu, et al. Expression of SR-PSOX, a Novel Cell-Surface Scavenger Receptor for Phosphatidylserine and Oxidized LDL in Human Atherosclerotic Lesions Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1796 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.Y Li, H.J Chen, and J.L Mehta Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation Cardiovasc Res, October 1, 2001; 52(1): 130 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Welch, S. Bretschger, N. Latib, M. Bezouevski, Y. Guo, N. Pleskac, C.-P. Liang, C. Barlow, H. Dansky, J. L. Breslow, et al. Localization of atherosclerosis susceptibility loci to chromosomes 4 and 6 using the Ldlr knockout mouse model PNAS, July 3, 2001; 98(14): 7946 - 7951. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kataoka, N. Kume, S. Miyamoto, M. Minami, M. Morimoto, K. Hayashida, N. Hashimoto, and T. Kita Oxidized LDL Modulates Bax/Bcl-2 Through the Lectinlike Ox-LDL Receptor-1 in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 955 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shimaoka, N. Kume, M. Minami, K. Hayashida, T. Sawamura, T. Kita, and S. Yonehara LOX-1 Supports Adhesion of Gram-Positive and Gram-Negative Bacteria J. Immunol., April 15, 2001; 166(8): 5108 - 5114. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L Mehta and Dayuan Li Facilitative interaction between angiotensin II and oxidised LDL in cultured human coronary artery endothelial cells Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S70 - S76. [Abstract] [PDF] |
||||
![]() |
S. J. White, S. A. Nicklin, T. Sawamura, and A. H. Baker Identification of Peptides That Target the Endothelial Cell-Specific LOX-1 Receptor Hypertension, February 1, 2001; 37(2): 449 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
X Shi, S Niimi, T Ohtani, and S Machida Characterization of residues and sequences of the carbohydrate recognition domain required for cell surface localization and ligand binding of human lectin-like oxidized LDL receptor J. Cell Sci., January 4, 2001; 114(7): 1273 - 1282. [Abstract] [PDF] |
||||
![]() |
M. Chen, M. Kakutani, M. Minami, H. Kataoka, N. Kume, S. Narumiya, T. Kita, T. Masaki, and T. Sawamura Increased Expression of Lectinlike Oxidized Low Density Lipoprotein Receptor-1 in Initial Atherosclerotic Lesions of Watanabe Heritable Hyperlipidemic Rabbits Arterioscler Thromb Vasc Biol, April 1, 2000; 20(4): 1107 - 1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Murase, N. Kume, H. Kataoka, M. Minami, T. Sawamura, T. Masaki, and T. Kita Identification of Soluble Forms of Lectin-Like Oxidized LDL Receptor-1 Arterioscler Thromb Vasc Biol, March 1, 2000; 20(3): 715 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kataoka, N. Kume, S. Miyamoto, M. Minami, T. Murase, T. Sawamura, T. Masaki, N. Hashimoto, and T. Kita Biosynthesis and Post-translational Processing of Lectin-like Oxidized Low Density Lipoprotein Receptor-1 (LOX-1). N-LINKED GLYCOSYLATION AFFECTS CELL-SURFACE EXPRESSION AND LIGAND BINDING J. Biol. Chem., February 25, 2000; 275(9): 6573 - 6579. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kakutani, T. Masaki, and T. Sawamura A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 PNAS, January 4, 2000; 97(1): 360 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shimaoka, N. Kume, M. Minami, K. Hayashida, H. Kataoka, T. Kita, and S. Yonehara Molecular Cloning of a Novel Scavenger Receptor for Oxidized Low Density Lipoprotein, SR-PSOX, on Macrophages J. Biol. Chem., December 22, 2000; 275(52): 40663 - 40666. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Shiffman, T. Mikita, J. T. N. Tai, D. P. Wade, J. G. Porter, J. J. Seilhamer, R. Somogyi, S. Liang, and R. M. Lawn Large Scale Gene Expression Analysis of Cholesterol-loaded Macrophages J. Biol. Chem., November 22, 2000; 275(48): 37324 - 37332. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |